Search
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization. … [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354]
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational[A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical … [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605]
Enzacamene
go.drugbank.com/drugs/DB11219ApprovedWhile its effects on the human reproductive system as an endocrine disruptor are being investigated, its use in over-the-counter and cosmetic products is approved by Health Canada.
Mixtures: But First WaterEtoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawn[T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]
Ferric maltol
go.drugbank.com/drugs/DB15598ApprovedInvestigational[L10974] On December 22, 2025, the FDA expanded this indication to include pediatric patients aged 10 years and older. [L54873,L54878]
Fenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnIn 2006 and 2009, the FDA issued warnings that it had been detected in diet pills sold online, and imported from foreign manufacturers. … It is listed as an illicit substance in many countries due to addiction issues and listed as a prohibited substance by the World Anti-Doping Agency.
Riltozinameran
go.drugbank.com/drugs/DB17095ApprovedInvestigational[L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]
Donidalorsen
go.drugbank.com/drugs/DB18751ApprovedInvestigationalHereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of severe swelling induced by excessive production of bradykinin. … [L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783]
Ergoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA.